BEIJING--(BUSINESS WIRE)--Genetron Health, a China-based precision oncology company that provides full cycle cancer management solutions, announced it was selected to participate in 2019 China National Key Research and Development Project led by the China National Center for Biotechnology Development, to support research on development and evaluation of liquid biopsy technology for early screening of cancer.
Led by the Cancer Hospital Chinese Academy of Medical Sciences, this research, which is part of the 2019 China National Key Research and Development Project, aims for a technology breakthrough in liquid biopsy technology of early screening and treatment of malignancy by December 2021, which would establish a high-sensitivity, high-specificity, high-efficiency, and cost-effective diagnosis technology system.
As a pioneer in the innovation of cancer early screening technology, Genetron Health will leverage its independently developed Mutation Capsule technology to detect tumor-specific mutations and methylation in cell free DNA (cfDNA) , and establish models for cancer early diagnosis.
In addition, Genetron Health plans to commercialize the early screening product by conducting prospective cohort studies on a large sample size regarding lung cancer and digestive system cancers in selected areas. Study results will be compared and examined against widely applied screening technologies and will apply for IVD registration as testing assays.
In 2019, Proceedings of the National Academy of Sciences of the USA (PNAS) published promising results of a pilot study on a liver cancer early screening study using cfDNA and protein markers, a collaborative effort between Genetron Health and the National Cancer Center/ Cancer Hospital Chinese Academy of Medical Sciences.
“Genetron Health is working diligently to develop technologies and products for early screening of malignancy,” said Mr. Sizhen Wang, co-founder and CEO of Genetron Health, “The company is expanding the early screening technology platform to cover multiple cancers, accelerating the design of new assays and starting the commercialization to benefit the public.”
About Genetron Health
Genetron Health is a leading and fast-growing precision oncology company in China that specializes in cancer molecular profiling. We harness advanced technologies in molecular biology and data science to transform cancer treatment. Driven by our mission to transform cancer treatment and prevention globally by driving technological innovation and accelerating the adoption of precision oncology medicine, we offer our products and services through three business units: diagnosis and monitoring, early screening, and development services. Genetron was founded in 2015 and is based in Beijing, China. For more information, please visit www.genetronhealth.com.
